Insider Transactions in Q4 2025 at Bridge Bio Pharma, Inc. (BBIO)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2025
|
Andrew Lo Director |
SELL
Open market or private sale
|
Indirect |
55,000
-30.37%
|
$3,575,000
$65.64 P/Share
|
|
Nov 17
2025
|
Randal W. Scott Director |
SELL
Open market or private sale
|
Direct |
10,000
-26.23%
|
$660,000
$66.57 P/Share
|
|
Nov 17
2025
|
Randal W. Scott Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+31.66%
|
$160,000
$16.75 P/Share
|
|
Nov 17
2025
|
Andrew Lo Director |
SELL
Open market or private sale
|
Direct |
40,599
-44.26%
|
$2,679,534
$66.84 P/Share
|
|
Nov 17
2025
|
Thomas Trimarchi President and CFO |
SELL
Open market or private sale
|
Direct |
16,934
-2.14%
|
$1,117,644
$66.51 P/Share
|
|
Nov 16
2025
|
Neil Kumar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,855
-11.42%
|
$2,168,430
$66.39 P/Share
|
|
Nov 16
2025
|
Neil Kumar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
64,697
+7.35%
|
-
|
|
Nov 16
2025
|
Thomas Trimarchi President and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,317
-5.06%
|
$1,406,922
$66.39 P/Share
|
|
Nov 16
2025
|
Maricel Apuli Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,781
-3.49%
|
$315,546
$66.39 P/Share
|
|
Nov 12
2025
|
Hannah Valantine Director |
SELL
Open market or private sale
|
Direct |
25,484
-77.34%
|
$1,681,944
$66.07 P/Share
|
|
Nov 12
2025
|
Hannah Valantine Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,484
+43.61%
|
$1,223,232
$48.45 P/Share
|
|
Nov 07
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.48%
|
$2,440,000
$61.93 P/Share
|
|
Nov 06
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.47%
|
$2,520,000
$63.62 P/Share
|
|
Nov 06
2025
|
Ronald J Daniels Director |
SELL
Open market or private sale
|
Direct |
61,031
-78.22%
|
$3,844,953
$63.72 P/Share
|
|
Nov 06
2025
|
Ronald J Daniels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
61,031
+43.89%
|
$2,075,054
$34.65 P/Share
|
|
Oct 29
2025
|
Frank Mccormick Director |
SELL
Open market or private sale
|
Indirect |
198,359
-4.89%
|
$13,290,053
$67.39 P/Share
|
|
Oct 27
2025
|
Frank Mccormick Director |
SELL
Open market or private sale
|
Indirect |
1,641
-0.19%
|
$106,665
$65.0 P/Share
|
|
Oct 09
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-1.38%
|
$2,160,000
$54.8 P/Share
|
|
Oct 08
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.68%
|
$2,160,000
$54.74 P/Share
|